Dov A. Goldstein M.D., Director at NeuBase Therapeutics, Inc. (NBSE), bought 8,000 shares at $4.75 ($38K) on 2021-06-18, disclosed to the SEC on 2021-06-21.
Open-market purchase of $38k NBSE by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| Filing → |
| NBSE | BUY | 2020-05-04 | $60K | — | Filing → |
| ESPR | SELL | 2017-03-23 | $66.7M | — | Filing → |
| CEMP | SELL | 2017-03-09 | $533K | — | Filing → |